You are viewing a preview of...

Anti-CCR6 mAb for Autoimmune Diseases

Monoclonal antibody targeting CCR6 to enable an “immune system reset” as a therapeutic for several autoimmune diseases

Background

C-C chemokine receptor type 6 (CCR6) is expressed by Th17, Th22, Tc17, γδ-T cells and group 3 innate lymphoid cells (ILC3). CCR6 is crucial in the migration of the immune cells during the course of certain inflammatory diseases. CCR6 is the only known receptor for CCL20, which is widely expressed including non-lymphoid tissue. Findings suggest that the CCR6-CCL20 axis is involved in multiple autoimmune diseases, both in human and mouse.

Technology Overview

Researchers at Monash University have developed highly potent antibodies against CCR6 with distinct functionalities (i.e. depleting or blocking). The MoA is ablation of pathogenic immune cells expressing CCR6 (predominantly Th17/Th22) using a depleting antibody.

Further Details:

Robert et al. Essential role for CCR6 in certain inflammatory diseases

Log in or create a free account to continue reading